Sangamo Therapeutics, Inc.
SGMO
$0.4831
-$0.0169-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,238.25% | 269.78% | 425.77% | -94.79% | -99.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,238.25% | 269.78% | 425.77% | -94.79% | -99.70% |
| Cost of Revenue | -27.55% | -53.49% | -51.42% | -58.10% | -43.22% |
| Gross Profit | 44.74% | 67.00% | 145.46% | 53.32% | -137.38% |
| SG&A Expenses | -14.52% | -26.01% | -37.86% | -0.47% | -35.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.33% | -47.83% | -48.76% | -46.57% | -41.42% |
| Operating Income | 37.20% | 58.28% | 121.15% | 41.67% | -161.58% |
| Income Before Tax | 37.79% | 60.67% | 110.46% | 70.15% | -329.71% |
| Income Tax Expenses | 21.43% | -56.99% | -93.07% | 101.18% | -49.48% |
| Earnings from Continuing Operations | 37.67% | 61.20% | 110.25% | 68.45% | -332.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.67% | 61.20% | 110.25% | 68.45% | -332.29% |
| EBIT | 37.20% | 58.28% | 121.15% | 41.67% | -161.58% |
| EBITDA | 37.50% | 59.08% | 125.39% | 39.70% | -157.15% |
| EPS Basic | 48.97% | 67.22% | 107.65% | 74.00% | -317.07% |
| Normalized Basic EPS | 44.09% | 66.07% | 119.28% | 49.35% | -152.21% |
| EPS Diluted | 48.97% | 65.86% | 106.78% | 74.00% | -326.83% |
| Normalized Diluted EPS | 44.09% | 66.07% | 118.74% | 49.35% | -152.41% |
| Average Basic Shares Outstanding | 22.14% | 18.33% | 17.60% | 16.99% | 7.01% |
| Average Diluted Shares Outstanding | 22.14% | 18.33% | 20.97% | 16.99% | 6.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |